BLOK METODE BELAJAR

EVIDENCE BASED MEDICINE

Disusun Oleh:
NAMA : HANNY SILVIANA
NPM : 1102016080

FAKULTAS KEDOKTERAN
UNIVERSITAS YARSI
2016
Skenario
Ibu Ina akhir-akhir ini merasakan rasa nyeri pada bagian perut dan ulu hatinya, ia
menyadari bahwa pola makan yang tidak teratur akhir-akhir ini menjadi penyebab dari rasa
nyerinya itu. Akhirnya ia pun berkonsultasi ke dokter, dokter mendiagnosa bahwa Ibu Ina
menderita Dyspepsia yang disebabkan karena naiknya produksi asam lambung. Dokter pun
menyarankan Ibu Ina untuk mengonsumsi obat lansoprazole, meskipun sebelumnya ia juga
pernah mengalami rasa nyeri yang sama dan mengonsumsi obat omeprazole.
Pertanyaan klinis : Apakah Lansoprazole lebih efektif mengatasi Dyspepsia daripada
Omeprazole ?
P (Person/Population) : Ibu Ina yang didiagnosa terkena Dyspepsia
I (Intervention) : Lansoprazole
C (Comparison) : Omeprazole
O (Outcome) : Menurunkan produksi asam lambung
Keyword : Dyspepsia AND lansoprazole AND omeprazole AND NDI
Limitation : 2011 2016
Title : Effectiveness Omeprazole And Lansoprazole In Dyspepsia Patient With
Nepean Dyspepsia Index
Web Source : https://scholar.google.co.id/
Result :
1. The comparative study of the effectiveness of cimetidine, ranitidine,
famotidine, and omeprazole in treatment of children with dyspepsia
2. Effectiveness omeprazole and lansoprazole in dyspepsia patient
with nepean dyspepsia index
3. Guidelines for the treatment of functional dyspepsia
4. Proton pump inhibitors induced hyperhidrosis: important but not
recognized
5. Proton pump inhibitor therapy and potential long-term harm
6. Saccharomyces boulardii enhances the Helicobacter pylori
eradication rates of omeprazole-triple therapy in patients with
peptic ulcer disease or functional dyspepsia
7. Guidelines for the management of Helicobacter pylori infection in
Italy: the III Working Group Consensus Report 2015
8. Prevalence and appropriateness of drug prescriptions for peptic
ulcer and gastro-esophageal reflux disease in a cohort of
hospitalized elderly
9. Why dyspepsia can occur without organic disease: pathogenesis and
management of functional dyspepsia
10. [PDF] , randomized, prospective study of 14-day ranitidine
bismuth citrate-vs. lansoprazole-based triple therapy for the
eradication of Helicobacter pylori in dyspeptic
11. Prospective Randomized Trial of Esomeprazole versus
Lansoprazole and Omeprazole Based Triple Therapy for H. Pylori
Eradication in an Iranian Population
12. Citation of This Article

13. Review article: current treatment options and management of

functional dyspepsia
14. Integrative treatment of reflux and functional dyspepsia in
children
15. Omeprazole-induced myositis in a Child receiving triple
therapy for Helicobacter pylori Infection
16. The Dentist's Quick Guide to Medical Conditions
17. Proton Pump Inhibitors in Functional Dyspepsia
18. Safety and Efficacy of Lansoprazole Injection in Upper
Gastrointestinal Bleeding: a Postmarketing Surveillance Conducted
in Indonesia
19. Probiotics and Helicobacter pylori
20. Guidelines for the Diagnosis and Treatment of Helicobacter
pylori Infection in Korea
21. Review article: endpoints used in functional dyspepsia drug
therapy trials
22. Lifestyle factors and efficacy of lifestyle interventions in
gastroesophageal reflux disease patients with functional dyspepsia:
primary care perspectives from the
23. Is There a Role for Probiotics in Helicobacter pylori Therapy?
24. Proton pump inhibitors overuse: only inappropriate
prescriptions or further iatrogenic damage?
25. Efficacy of acupuncture treatment for functional dyspepsia: A
systematic review and meta-analysis
26. Growth-inhibiting, bactericidal, and urease inhibitory effects of
Paeonia lactiflora root constituents and related compounds on
antibiotic-susceptible and-resistant
27. Trends in the eradication rates of Helicobacter pylori infection
in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13
years
28. Laparoscopic antireflux surgery vs esomeprazole treatment for
chronic GERD: the LOTUS randomized clinical trial
29. A randomized study comparing levofloxacin, omeprazole,
nitazoxanide, and doxycycline versus triple therapy for the
eradication of Helicobacter pylori
30. 5 decrease of cross shift and cross week blood cholinesterase
activity in pesticide sprayer of onion farmers
31. Functional Dyspepsia
32. Absence of Helicobacter pylori high tetracycline resistant 16S
rDNA AGA926-928TTC genotype in gastric biopsy specimens from
dyspeptic patients of a city in
33. How often do you fail to take all of your medication?
34. Method for the treatment of gastrointestinal disorders
35. Metaanalysis: esomeprazole or rabeprazole vs. first
generation pump inhibitors in the treatment of Helicobacter pylori
infection
36. Recent advances in noncardiac chest pain in Korea
37.
38. Efficacy of DA-9701 (Motilitone) in functional dyspepsia
compared to pantoprazole: a multicenter, randomized, double-blind,
non-inferiority study
39. The First-Line Eradication Rate for Helicobacter pylori Infection
in Functional Dyspepsia Patients
40. Eradication of Helicobacter pylori in Children by Triple Therapy
Regimens of Amoxicillin, Omeprazole, and Clarithromycin or
Azithromycin
41. Paediatric Helicobacter pylori practice in the United Kingdom:
a BSPGHAN survey
42. Surgery for Type IIIIV hiatal hernia: anatomical recurrence
and global results after elective treatment of short oesophagus with
open and minimally invasive surgery
43. Expression comparison of azithromycin and clarithromycin in
triple-therapy regimens for eradication of Helicobacter pylori in
hemodialysis patients
44. Gastroesophageal Reflux Disease: Current Evaluation and
Management
45. Chiral Separation of the Enantiomers of Omeprazole and
Pantoprazole by Capillary Electrophoresis
46. Functional dyspepsia in children
47. Focus on current trends in the treatment of Helicobacter pylori
infection: An update
48. Effectiveness of Triple Therapy Regimens in the Eradication of
Helicobacter pylori in Patients with Uninvestigated Dyspepsia in Ekiti
State, Nigeria
49. Characteristics of refractory gastroesophageal reflux disease
(GERD) symptoms-is switching proton pump inhibitors based on the
patient's CYP2C19 genotype an
50. Review article: adherence to Rome criteria in therapeutic trials
in functional dyspepsia
51. Gastroesophageal Reflux Disease: Current Evaluation and
Management
52. Endoscopic findings of dyspeptic patients unresponsive to
proton pump inhibitors
53. Guidance on the use of over-the-counter proton pump
inhibitors for the treatment of GERD
54. Effects of rabeprazole on bone metabolic disorders in a
gastrectomized rat model
55. Visceral hypersensitivity and electromechanical dysfunction as
therapeutic targets in pediatric functional dyspepsia

56. Significance of gastroesophageal refluxate in relation to

physical, chemical, and spatiotemporal characteristics in
symptomatic intensive care unit neonates
57. Systematic review: the use of proton pump inhibitors and
increased susceptibility to enteric infection
58. Expert position paper on the use of proton pump inhibitors in
patients with cardiovascular disease and antithrombotic therapy
59. Quadruple therapy for eradication of Helicobacter pylori
60. Examining the relationship between vitamin D levels and
Helicobacter pylori infection and its effect on the hypothalamic-
pituitary-adrenal axis in dyspeptic patients
61. Treatment of Helicobacter pylori infection: current status and
future concepts
62. Study of controlled degradation processes and electrophoretic
behaviour of omeprazole and its main degradation products using
diode-array and ESI-IT-MS detection
63. The association between the use of proton pump inhibitors
and the risk of hypomagnesemia: a systematic review and meta-
analysis
64. Clinical utility of esomeprazole for treatment of
gastroesophageal reflux disease in pediatric and adolescent patients
65. Current Concepts in the Medical Treatment
66. Efficacy of mosapride plus proton pump inhibitors for
treatment of gastroesophageal reflux disease: A systematic review
67. Is it necessary to increase the dose of levothyroxine in
patients with hypothyroidism who use omeprazole?
68. Proton pump inhibitors alter gastric microbiota composition in
subjects with upper gastrointestinal symptoms: preliminary
69. Review of Helicobacter pylori infection and chronic renal
failure
70. Association of a probiotic to a Helicobacter pylori eradication
regimen does not increase efficacy or decreases the adverse effects
of the treatment: a
71. Gastroparesis in children
72. Proton Pump Inhibitors in Gastroprotection: Prevention and
Healing of Nonsteroidal Anti-Inflammatory Drug-, Aspirin-, and
Cyclooxygenase-2 Inhibitor-Induced
73. Overuse of proton pump inhibitors
74. Azithromycin based triple therapy versus standard
clarithromycin based triple therapy in eradication of Helicobacter
pylori infection in Iran: a randomized
75. Prevalence of gastroesophageal reflux disease symptoms and
effects of esomeprazole on the quality of life related to reflux and
dyspepsia in patients on maintenance
76. Update on triple therapy for eradication of Helicobacter pylori:
current status of the art
77. Treatment of pharmacological-induced hypochlorhydria
78. Pharmacological Treatment for Functional Dyspepsia and
Irritable Bowel Syndrome: Current Standards and Promising
Therapies
79. Potensi Interaksi Obat Pada Pasien Gangguan Lambung
(Dispepsia, Gastritis, Tukak Peptik) Rawat Inap Di Rumah Sakit
Keluarga Sehat Pati Tahun 2015